STM :癌症免疫疗法使多名白血病患者病情完全缓解

2014-02-20 佚名 爱爱医

美国研究人员19日报告说,他们利用癌症免疫疗法,使得多名急性白血病患者病情完全缓解,其中一名患者的完全缓解期已达两年。研究人员称,虽然还不能断定是否彻底治愈,但这种实验性疗法无疑为治疗白血病乃至其他癌症带来了希望。 癌症免疫疗法是指基于患者自身免疫细胞的一种基因工程疗法。美国斯隆-凯特林癌症研究所研究人员19日在美国《科学转化医学》杂志上报告说,他们首先从患者体内取出T细胞,然后利用基因工程进行

美国研究人员19日报告说,他们利用癌症免疫疗法,使得多名急性白血病患者病情完全缓解,其中一名患者的完全缓解期已达两年。研究人员称,虽然还不能断定是否彻底治愈,但这种实验性疗法无疑为治疗白血病乃至其他癌症带来了希望。

癌症免疫疗法是指基于患者自身免疫细胞的一种基因工程疗法。美国斯隆-凯特林癌症研究所研究人员19日在美国《科学转化医学》杂志上报告说,他们首先从患者体内取出T细胞,然后利用基因工程进行改造,使其识别白血病细胞中含有的CD19蛋白质,进而以此为突破点消灭白血病细胞。

参与研究的助理教授王秀艳向新华社记者介绍说,“这是一种活的药物,与传统化学药物不同。它们就像战士一样,会把肿瘤细胞杀死,最终自己也牺牲了”。

在临床试验中,共有16名B细胞急性淋巴性白血病患者接受治疗,结果有14人病情完全缓解,此后其中7人成功接受骨髓移植手术。B细胞急性淋巴性白血病是一种非常容易复发的癌症,治疗手段极为有限。

研究人员公布了两名患者的身份,其中来自宾夕法尼亚州的丹尼斯·比利有两年多没有复发白血病症状,已经重返教学岗位。另一名叫保罗·卡瓦利的患者是康涅狄格州一家餐馆的老板,病情完全缓解已经达到8个月。

不过,研究人员对使用“治愈”一词仍持谨慎态度。王秀艳说,完全缓解是指白血病已无法检测出来,但谁也不知道患者的完全缓解期会持续多长时间。

王秀艳表示,他们还在研究使用细胞疗法来治疗前列腺癌与淋巴癌等其他癌症,“尽管这只是实验性的,但细胞疗法,或更广泛地说免疫疗法,已经成为改变癌症治疗模式的一个范例”。

目前,癌症免疫疗法处于初级阶段。不过由于它的应用前景,美国《科学》杂志将其评为2013年最重要科学突破。

原始出处:

Marco L. Davila, Isabelle Riviere, Xiuyan Wang, Shirley Bartido, Jae Park, Kevin Curran, Stephen S. Chung, Jolanta Stefanski, Oriana Borquez-Ojeda, Malgorzata Olszewska, Jinrong Qu, Teresa Wasielewska, Qing He, Mitsu Fink, Himaly Shinglot, Maher Youssif, Mark Satter, Yongzeng Wang, James Hosey, Hilda Quintanilla, Elizabeth Halton, Yvette Bernal, Diana C. G. Bouhassira, Maria E. Arcila, Mithat Gonen, Gail J. Roboz, Peter Maslak, Dan Douer, Mark G. Frattini, Sergio Giralt, Michel Sadelain, and Renier Brentjens. Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia. Sci Transl Med, 19 February 2014; DOI:10.1126/scitranslmed.3008226

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1764960, encodeId=c65f1e64960b2, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1dc37824931, createdName=ms7524819409032184, createdTime=Sat Nov 29 20:25:00 CST 2014, time=2014-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677900, encodeId=632216e7900e2, content=<a href='/topic/show?id=29a8168130f' target=_blank style='color:#2F92EE;'>#STM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16813, encryptionId=29a8168130f, topicName=STM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d76127619556, createdName=gdsun, createdTime=Thu Aug 21 21:25:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9523, encodeId=bd1e952312, content=你好,我如何获得原始文献呢?谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fafa102772, createdName=EAAL, createdTime=Mon May 19 10:41:00 CST 2014, time=2014-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642439, encodeId=3ea51642439c8, content=<a href='/topic/show?id=842f458e61f' target=_blank style='color:#2F92EE;'>#完全缓解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45876, encryptionId=842f458e61f, topicName=完全缓解)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b5d22942638, createdName=小小小向日葵, createdTime=Tue Mar 11 02:25:00 CST 2014, time=2014-03-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1764960, encodeId=c65f1e64960b2, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1dc37824931, createdName=ms7524819409032184, createdTime=Sat Nov 29 20:25:00 CST 2014, time=2014-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677900, encodeId=632216e7900e2, content=<a href='/topic/show?id=29a8168130f' target=_blank style='color:#2F92EE;'>#STM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16813, encryptionId=29a8168130f, topicName=STM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d76127619556, createdName=gdsun, createdTime=Thu Aug 21 21:25:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9523, encodeId=bd1e952312, content=你好,我如何获得原始文献呢?谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fafa102772, createdName=EAAL, createdTime=Mon May 19 10:41:00 CST 2014, time=2014-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642439, encodeId=3ea51642439c8, content=<a href='/topic/show?id=842f458e61f' target=_blank style='color:#2F92EE;'>#完全缓解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45876, encryptionId=842f458e61f, topicName=完全缓解)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b5d22942638, createdName=小小小向日葵, createdTime=Tue Mar 11 02:25:00 CST 2014, time=2014-03-11, status=1, ipAttribution=)]
    2014-08-21 gdsun
  3. [GetPortalCommentsPageByObjectIdResponse(id=1764960, encodeId=c65f1e64960b2, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1dc37824931, createdName=ms7524819409032184, createdTime=Sat Nov 29 20:25:00 CST 2014, time=2014-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677900, encodeId=632216e7900e2, content=<a href='/topic/show?id=29a8168130f' target=_blank style='color:#2F92EE;'>#STM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16813, encryptionId=29a8168130f, topicName=STM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d76127619556, createdName=gdsun, createdTime=Thu Aug 21 21:25:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9523, encodeId=bd1e952312, content=你好,我如何获得原始文献呢?谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fafa102772, createdName=EAAL, createdTime=Mon May 19 10:41:00 CST 2014, time=2014-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642439, encodeId=3ea51642439c8, content=<a href='/topic/show?id=842f458e61f' target=_blank style='color:#2F92EE;'>#完全缓解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45876, encryptionId=842f458e61f, topicName=完全缓解)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b5d22942638, createdName=小小小向日葵, createdTime=Tue Mar 11 02:25:00 CST 2014, time=2014-03-11, status=1, ipAttribution=)]
    2014-05-19 EAAL

    你好,我如何获得原始文献呢?谢谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1764960, encodeId=c65f1e64960b2, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1dc37824931, createdName=ms7524819409032184, createdTime=Sat Nov 29 20:25:00 CST 2014, time=2014-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1677900, encodeId=632216e7900e2, content=<a href='/topic/show?id=29a8168130f' target=_blank style='color:#2F92EE;'>#STM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16813, encryptionId=29a8168130f, topicName=STM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d76127619556, createdName=gdsun, createdTime=Thu Aug 21 21:25:00 CST 2014, time=2014-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9523, encodeId=bd1e952312, content=你好,我如何获得原始文献呢?谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fafa102772, createdName=EAAL, createdTime=Mon May 19 10:41:00 CST 2014, time=2014-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642439, encodeId=3ea51642439c8, content=<a href='/topic/show?id=842f458e61f' target=_blank style='color:#2F92EE;'>#完全缓解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45876, encryptionId=842f458e61f, topicName=完全缓解)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b5d22942638, createdName=小小小向日葵, createdTime=Tue Mar 11 02:25:00 CST 2014, time=2014-03-11, status=1, ipAttribution=)]

相关资讯

Nat Med:德国研究发现一种肾癌疫苗安全有效

肾癌    新一期英国《自然-医学》杂志刊登报告说,德国研究人员对一种肾癌疫苗进行了人体临床试验,结果显示它安全有效,与化学疗法相比效果更好,并且副作用更少。   德国蒂宾根大学等机构的研究人员报告说,这种代号为IMA901的疫苗可以促使人体自身免疫系统抵抗癌症。研究人员对96名肾癌患者展开了临床试验,结果显示疫苗安全,没有太大的副作用,与最新的化疗相比可更好地延长患者的生命。